PREPIT 125MG/80MG KIT

About

Prepit 125mg/80mg Kit contains aprepitant, a selective neurokinin-1 (NK1) receptor antagonist that works by blocking the binding of substance P, a neuropeptide, to the NK1 receptor. This mechanism is crucial in preventing both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV). The kit typically contains a higher dose for the first day and a lower dose for subsequent days, reflecting the pharmacokinetic profile and the need for sustained NK1 receptor blockade. It is often used in combination with other antiemetics, such as 5-HT3 receptor antagonists and corticosteroids, to provide comprehensive CINV prophylaxis, particularly in patients receiving highly emetogenic chemotherapy regimens. Its long duration of action makes it effective against delayed CINV, which can be particularly challenging to manage.

Uses

• Prevention of acute chemotherapy-induced nausea and vomiting.
• Prevention of delayed chemotherapy-induced nausea and vomiting.
• Prophylaxis of postoperative nausea and vomiting.
• Used in combination with other antiemetics for optimal effect.

Directions For Use

Take as directed by your physician, usually starting before chemotherapy. Follow the specific dosing schedule provided in the kit.

Benefits

• Highly effective in preventing both acute and delayed CINV.
• Significantly reduces the incidence and severity of nausea.
• Improves patient comfort and quality of life during chemotherapy.
• Works synergistically with other antiemetic agents.
• Long duration of action provides sustained protection.
• Reduces the need for rescue antiemetics.

Side Effects

• Fatigue
• Hiccups
• Dizziness
• Diarrhea
• Constipation
• Headache
• Loss of appetite
• Abdominal pain
• Heartburn
• Weakness
• Neutropenia
• Increased liver enzymes

Safety Measures

• Alcohol - Alcohol consumption should be limited or avoided as it may exacerbate side effects like dizziness or drowsiness.
• Pregnancy - Use with caution during pregnancy only if the potential benefit outweighs the potential risk to the fetus. Consult a doctor.
• Breastfeeding - It is unknown if aprepitant is excreted in human milk. Breastfeeding is generally not recommended during treatment.
• Liver - Use with caution in patients with severe hepatic impairment; dose adjustments may be necessary.
• Kidney - No dose adjustment is typically required for patients with renal impairment.
• Lung - Generally safe for use in patients with lung conditions; no specific precautions are usually needed.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.